PDF
ZENODO
Published
2025-06-09
Section
Articles
How to Cite
How to Cite
COMPARATIVE CHARACTERISTICS OF CLASSICAL AND NEW ORAL ANTICOAGULANTS
Yusupov Ziyodulla Yuldoshevich
1st-year Clinical Residency Student, Samarkand State Medical University
Lutfullin Said Irekovich
1st-year Clinical Residency Student, Samarkand State Medical University
Rakhmatillaev Rabbonjon Nomoz ugli
1st-year Clinical Residency Student, Samarkand State Medical University
Keywords: oral anticoagulants, warfarin, novel oral anticoagulants, NOACs, rivaroxaban, apixaban, dabigatran, thrombosis prevention, anticoagulation therapy, clinical comparison.
Abstract
This article presents a comparative analysis of classical and new oral anticoagulants, highlighting their mechanisms of action, pharmacokinetic properties, clinical applications, advantages, and limitations. Classical anticoagulants, such as warfarin, have been widely used for decades but require regular monitoring and dietary restrictions. In contrast, novel oral anticoagulants (NOACs), including rivaroxaban, apixaban, and dabigatran, offer improved safety profiles, predictable pharmacokinetics, and fewer interactions. The article emphasizes the importance of individualized patient care when choosing the appropriate anticoagulant therapy and outlines current clinical guidelines and research findings related to anticoagulation management.
References
1. Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361(12), 1139–1151.
2. Patel, M. R., Mahaffey, K. W., Garg, J., et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 365(10), 883–891.
3. Granger, C. B., Alexander, J. H., McMurray, J. J., et al. (2011). Apixaban versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 365(11), 981–992.
4. Ruff, C. T., Giugliano, R. P., Braunwald, E., et al. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. The Lancet, 383(9921), 955–962.
5. January, C. T., Wann, L. S., Calkins, H., et al. (2019). 2019 AHA/ACC/HRS Focused Update on atrial fibrillation management. Journal of the American College of Cardiology, 74(1), 104–132.
6. Karimov, M. M., & Ergashev, A. A. (2022). Clinical pharmacology: A guide for medical students. Tashkent: TMA Publishing.
7. Rakhmatullaev, R. N., & Muminov, Z. M. (2021). Modern approaches in anticoagulant therapy. Uzbek Medical Journal, 6(3), 45–50.
8. Tursunov, I. I., & Abdullaeva, D. K. (2020). Clinical features of using NOACs in elderly patients. Journal of Medical Science of Uzbekistan, 4(2), 61–67.
9. European Medicines Agency (EMA). (2023). Direct oral anticoagulants: Review of bleeding risks and indications. Retrieved from https://www.ema.europa.eu
10. U.S. Food and Drug Administration (FDA). (2022). Anticoagulant Drugs - Clinical Considerations. Retrieved from https://www.fda.gov
